Zimmer Biomet deal fallout: new leader in hips and knees, S and N to lose out?
This article was originally published in Clinica
Zimmer’s $13.35bn purchase of Biomet, agreed last week, looks set to create a new market leader in large joint reconstruction, according to Goldman Sachs analyst David Roman. He estimates that the new combined company has 39% of the sector, which comprises hip and knee implants, followed by Johnson & Johnson with 23%, Stryker with 21%, then Smith & Nephew with 12%.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.